CIM
PDLI

Contravisory Investment Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Contravisory Investment Management’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-16,750
Closed -$129K – 148
2013
Q2 		$129K Buy
+16,750
New +$131K 0.03% 78

Other funds holding PDLI

Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.01B AUM 24.74% 1-Year Est. Return

Contravisory Investment Management's PDLI Position: Q3 2013 in Review

Contravisory Investment Management sold out of PDL BioPharma, Inc. (PDLI) in Q3 2013, closing a stake of 16,750 shares — an estimated $129K sold.

Contravisory Investment Management first reported a position in PDLI in Q2 2013 and held it in 1 quarter. The position peaked at $129K in Q2 2013. 212 funds tracked by Wall St. Rank hold PDLI as of Q3 2013.

  • Contravisory Investment Management reported no remaining PDL BioPharma, Inc. position as of Q3 2013 after selling out during the quarter.
  • Contravisory Investment Management sold 16,750 PDL BioPharma, Inc. shares in Q3 2013, an estimated $129K.
  • Contravisory Investment Management first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 1 quarter.
  • Contravisory Investment Management's PDL BioPharma, Inc. position peaked at $129K in Q2 2013.
  • 212 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q3 2013.

Based on Contravisory Investment Management's 13F filing for Q3 2013, filed 11 Oct 2013.